
Record of Telephone Conversation, September 28, 2012 - Flucelvax

 
 

Submission Type: BLA    Submission ID: 125408/0    Office: OVRR

Product:

Influenza Vaccine (MDCK Cells)

Applicant:

Novartis Vaccines and Diagnostics, Inc.

Telecon Date/Time: 28-Sep-2012 04:34 PM        Initiated by FDA? Yes

Telephone Number: Communicated via e-mail

Communication Categorie(s):

1. Information Request

Author: TIMOTHY FRITZ

Telecon Summary:

-(b)(4)- assay for BPL quantitation.

FDA Participants: Timothy Fritz

Non-FDA Participants: Matthew Gollwitzer

Trans-BLA Group: No

Related STNs: None

Related PMCs: None

Telecon Body:

From:                    Fritz, Timothy

Sent:                      Friday, September 28, 2012 4:34 PM

To:                         'Gollwitzer, Matthew'

Subject:                 CBER Information Request for STN 125408 (Flucelvax)

 

Importance:           High

Dear Mr. Gollwitzer-

 

Our review of Novartis' Flucelvax BLA submission (STN 125408) is ongoing. We have the following requests for additional information:

 

1. In the -(b)(4)- assay validation report for the measurement of residual -----(b)(4)-------- BPL, we noted that the sample matrix may exert some interference. For specificity testing, results for two of the three tested -----(b)(4)-------- showed that the --(b)(4)-- matrix substantially reduced BPL quantitation (see Table below comparing spiked sample to Blank 3 results). Please provide a justification for how this assay can be used for the measurement of residual BPL in the                 -----(b)(4)-------- given this observed interference.

 

The Summary below is based on BPL limit test validation report V.03.REP.P141_01 (Fig 1-21) pg 11-13, submitted in Amendment 33.

 


[(b)(4)]

 

 

2. Please provide validation data to demonstrate the accuracy and robustness of this assay.

 

3. Please elaborate on the importance of the Limit Test Performance in the System Suitability Test and explain how the acceptance criteria is being established.

 

Please submit the requested information as an amendment to STN 125408 as soon as possible. We recommend that you restate each item and follow it with your explanation or clarification. Use of this format helps organize the relevant information and provides a self-contained document that facilitates future reference.

 

If you have any questions, please contact the Regulatory Project Manager, Drs Brenda Baldwin or Timothy Fritz, at 301-796-2640 or via e-mail.

 

Thank you.

Timothy A. Fritz, Ph.D. 
Microbiologist 
FDA/CBER/OVRR/DVRPA/CMC2 
WOC2 HFM-478
1451 Rockville Pike 
Rockville, MD 20852 
Phone: 301-796-2640 
Fax: 301-827-1597

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.